Data Bytes: Cellectis remains active in allogeneic pipeline for multiple myeloma despite clinical hold

Even with the clinical hold on its Phase I trial of UCARTCS1A, Cellectis remains one of the most active companies developing allogeneic cell therapies for multiple myeloma, with another

Read the full 293 word article

How to gain access

Continue reading with a
two-week free trial.